ArticleBMC urology2025
Real-world evaluation of the efficacy and safety of disitamab vedotin (RC48) in urothelial carcinoma.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The efficacy and safety of disitamab vedotin plus immunotherapy in locally advanced or metastatic solid tumors: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Review
- Antibody-Drug Conjugates: Pharmacotherapeutic Properties and Future Perspectives.Pharmaceutics · 2026Review
- Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrothelial carcinoma (UC) is an aggressive malignancy with limited options for patients unresponsive to chemotherapy or immunotherapy. Disitamab vedotin (RC48), a HER2-targeted antibody-drug conjugate(ADC), has shown promising results in clinical trials, but real-world data are lacking.
methodsWe conducted a single-center retrospective study of patients with histologically confirmed UC who received RC48 alone or in combination with PD-1 inhibitors between August 2022 and June 2024. Key inclusion criteria were at least one measurable lesion and adequate organ function; patients with incomplete records, concurrent active malignancies, or severe organ dysfunction precluding systemic therapy were excluded.
resultsA total of 71 patients were included. The ORR was 69.0%, including 15 complete and 34 partial responses. The median PFS was 24 months, and OS data were immature at cutoff. In subgroup analyses, patients receiving RC48 + PD-1 inhibitors achieved an ORR of 70.0% versus 63.6% with RC48 monotherapy. Grade ≥ 3 treatment-related adverse events occurred in 21.1% of patients, most commonly anemia and decreased appetite; events were generally manageable with supportive care and dose modification.
conclusionsRC48 showed encouraging activity and manageable safety in a real-world UC cohort. Prospective multicenter studies with longer follow-up are needed to validate these findings, compare monotherapy versus combination strategies, and define the optimal role of RC48 across UC disease stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.